Novel gene therapy platform delivering non-viral treatments to mucosal tissues and organs.
Location: Canada, Montreal (06), Montreal
Investors 1
| Date | Name | Website |
| 10.03.2024 | Omega Fund... | omegafunds... |
Mentions in press and media 10
| Date | Title | Description |
| 02.05.2024 | enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual M... | Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTREAL, May 2, 2024 /PRNewswire/ - enGene Hol... |
| 02.11.2023 | Lumira Ventures Portfolio Company enGene (Nasdaq: ENGN) Debuts as Publicly Traded Genetic Medicines Company | CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion |
| 27.05.2021 | Lumira Portfolio Company, enGene, Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial | BOSTON and MONTRÉAL, May 27, 2021: enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of ... |
| 27.05.2021 | enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial | |
| 03.12.2020 | enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer | |
| 02.11.2020 | enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer | |
| 29.10.2020 | enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis | |
| 09.01.2020 | enGene Expands Senior Management Team | BOSTON and MONTRÉAL /PRNewswire/ – enGene Inc., the biotechnology company developing rationally designed gene therapies targeted to mucosal tissues through its proprietary non-viral vector DDX® platform, today announced the appointments of ... |
| 29.05.2019 | enGene Appoints José M. Lora, Ph.D. as Chief Scientific Officer | MONTRÉAL and BOSTON, May 29, 2019 — enGene Inc., the high growth biotechnology company developing the Gene Pill™ – a robust, proprietary non-viral vector platform to deliver gene therapies via oral administration – today announced the appoi... |
| - | enGene | “Discover the future of genetic medicine. enGene is developing locally administered, non-viral gene therapies for rare genetic diseases.” |